In comparison with EGFR-TKI monotherapy, EGFR-TKIs combined with antiangiogenic drugs or chemotherapy significantly improved PFS in patients with advanced NSCLC having concomitant EGFR and TP53 mutations. The gene discussed is TP53; the disease is non-small cell lung carcinoma.